Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry

Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry

ObjectiveInterleukin (IL)-1 inhibitors are largely employed in patients with Still’s disease; in cases with refractory arthritis, IL-6 inhibitors have shown to be effective on articular inflammatory involvement. The aim of the present study is to assess any difference in the effectiveness of the IL-...

Full description

Bibliographic Details
Main Authors: Antonio Vitale, Valeria Caggiano, Maria Cristina Maggio, Giuseppe Lopalco, Giacomo Emmi, Jurgen Sota, Francesco La Torre, Piero Ruscitti, Elena Bartoloni, Giovanni Conti, Claudia Fabiani, Irene Mattioli, Carla Gaggiano, Fabio Cardinale, Lorenzo Dagna, Corrado Campochiaro, Roberto Giacomelli, Alberto Balistreri, Katerina Laskari, Abdurrahman Tufan, Gaafar Ragab, Ibrahim A. Almaghlouth, Ewa Więsik-Szewczyk, Rosa Maria Pereira, Bruno Frediani, Florenzo Iannone, Petros P. Sfikakis, Luca Cantarini
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Medicine
Subjects:
AOSD
adult onset Still’s disease
sJIA
systemic juvenile idiopathic arthritis
autoinflammatory diseases
biological therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1071732/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1071732/full

Similar Items